Investment Strategy
China Offers Still Compelling, Yet Complex, Investment Opportunities
China’s rising middle class and sustained innovation could drive growth in select businesses that are unaffected by new regulations.
Investment Strategy
Contenders vs. Pretenders: Seeking the True Leaders Amid a Lengthy Market Run
Global equities and valuations are at all-time highs, but threats loom. Dave Levanson, co-portfolio manager of Sands Capital's Global Growth strategy discusses how we’re investing in this environment, and why he thinks selectivity matters now as much as ever.
Investment Strategy
Life Sciences Revolution Enables Better Disease Diagnosis and Treatment
Technological advancements and biological breakthroughs have helped scientists better understand the causes of disease.
Investment Strategy
Seeking Digital Disruptors in International Markets
Ashraf Haque and Sunil Thakor, co-portfolio managers of Sands Capital’s International Growth strategy, dive into the opportunity set that can be found overseas.
Investment Strategy
China's Regulatory Environment and Its Implications for Growth Investors
Sr. Portfolio Managers Ashraf Haque and Brian Christiansen along with Research Analyst Judy Jiao discuss the Chinese regulatory environment and the potential impact these shifts could have on businesses and the economy.
Business Perspectives
What Matters Most
In this podcast series, we explore some of the trends and businesses that are propelling global innovation and changing the way we live and work today and into the future.
Investment Strategy
Contenders vs. Pretenders: Seeking the True Leaders Amid a Lengthy Market Run
Global equities and valuations are at all-time highs, but threats loom. Dave Levanson, co-portfolio manager of Sands Capital's Global Growth strategy discusses how we’re investing in this environment, and why he thinks selectivity matters now as much as ever.
Investment Strategy
Life Sciences Revolution Enables Better Disease Diagnosis and Treatment
Technological advancements and biological breakthroughs have helped scientists better understand the causes of disease.
Investment Strategy
Seeking Digital Disruptors in International Markets
Ashraf Haque and Sunil Thakor, co-portfolio managers of Sands Capital’s International Growth strategy, dive into the opportunity set that can be found overseas.
Investment Strategy
China's Regulatory Environment and Its Implications for Growth Investors
Sr. Portfolio Managers Ashraf Haque and Brian Christiansen along with Research Analyst Judy Jiao discuss the Chinese regulatory environment and the potential impact these shifts could have on businesses and the economy.
Business Perspectives
What Matters Most
In this podcast series, we explore some of the trends and businesses that are propelling global innovation and changing the way we live and work today and into the future.
Investment Strategy
Here’s Why Select Growth Businesses Can Continue to Add Value
Wes Johnston, co-portfolio manager, Select Growth strategy at Sands Capital shares his take on the value rally in this question and answer session.

Sands Capital exists to add value and enhance the wealth of our clients with prudence over time.

Singular Focus on Growth

Our strategies selectively allocate capital to leading public and private businesses, across the growth spectrum, around the world.

Cultivating Enduring Partnerships

Our skilled professionals are dedicated to delivering on our mission of adding value, while cultivating deep and enduring partnerships with our clients.

Announcements
Sands Capital Names Ian Ratcliffe to Executive Management Team
Ian has been instrumental in the development of the venture and private life sciences investing programs. His selection to the leadership team comes as Sands Capital continues to build its private market capabilities.
In The News
China’s Changing Priorities May Offer Opportunities in Select Businesses
Investors may look selectively to businesses supported by China’s emphasis on health and wellness, domestic brands, and higher-value manufacturing.
Announcements
Sands Capital Closes $560 Million Life Sciences Fund
This is Sands Capital’s second life sciences-dedicated fund, and the team will continue investing with an emphasis on private therapeutics, diagnostics, and life sciences tools businesses.